Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04174612 | AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance(AMELIORATE) | unknown | Phase 3 | 172 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05262465 | Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML | unknown | N/A | 300 | guomeiOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05252572 | Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05239689 | Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT03647800 | Study of APVO436 in Patients With AML or MDS | unknown | Phase 1 | 136 | Aptevo Research and Development LLCINDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05215015 | Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia | unknown | Early Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT03412292 | MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT04187495 | Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT01752062 | Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors(CML1012) | unknown | — | 148 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT01761890 | Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib(CML1113) | unknown | — | 147 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT03751917 | Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia(APL0618) | unknown | — | 100 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05152537 | FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia(NTU-CML-001) | unknown | — | 15 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05175508 | Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS | unknown | Phase 2 / Phase 3 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05023707 | Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT04722952 | PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML | unknown | Phase 3 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05127798 | RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old. | unknown | — | 50 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05123352 | Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies | unknown | — | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 17, 2021 | clinicaltrials |
| NCT04752527 | Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features | unknown | Phase 2 | 42 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT05017883 | TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia | unknown | N/A | 5 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04716114 | A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated(ALIVE) | unknown | Phase 3 | 315 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 2, 2021 | clinicaltrials |
| NCT05100303 | A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT04613622 | Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia | unknown | — | 500 | National Taiwan University HospitalOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT05092048 | A Study for PRO of CML in Real Word(Case-Only) | unknown | — | 10,000 | xunaOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT05080829 | Myeloid Mutations Register in R/R CML | unknown | N/A | 29 | Grupo Cooperativo de Hemopatías MalignasOTHER | 1 | Oct 18, 2021 | clinicaltrials |
| NCT05066958 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | unknown | Phase 1 / Phase 2 | 20 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT03257241 | A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old(PALG-AML1/2016) | unknown | Phase 3 | 582 | Polish Adult Leukemia GroupOTHER | 2 | Oct 1, 2021 | clinicaltrials |
| NCT03887156 | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft(Predictor2) | unknown | Phase 2 / Phase 3 | 227 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Sep 28, 2021 | clinicaltrials |
| NCT04631458 | Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis(Mascot) | unknown | — | 40 | Royal Free Hospital NHS Foundation TrustOTHER | 0 | Sep 16, 2021 | clinicaltrials |
| NCT02899169 | Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)(APL16) | unknown | Phase 3 | 110 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT04446741 | Molecular Diagnostic Platform for AML | unknown | — | 2,000 | PETHEMA FoundationOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05016752 | Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream Infection | unknown | — | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT05000801 | Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia | unknown | N/A | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT04991532 | Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells | unknown | — | 324 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT04931992 | Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.(MOLAM) | unknown | — | 100 | University Hospital, AngersOTHER_GOV | 1 | Jun 18, 2021 | clinicaltrials |
| NCT04906031 | Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations | unknown | Phase 2 | 5 | First Affiliated Hospital of Jinan UniversityOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04920500 | Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients | unknown | N/A | 16 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04069208 | IA14 Induction in Young Acute Myeloid Leukemia | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT01894477 | Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | unknown | Phase 2 | 102 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT04762485 | Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04904237 | Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML. | unknown | Phase 2 | 23 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT02530619 | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia | unknown | N/A | 26 | Northwestern UniversityOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT03795779 | CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT04884984 | Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT03080766 | The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype | unknown | Phase 2 | 20 | The University of Hong KongOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04818619 | TIGIT in Patients With Chronic Myeloid Leukemia | unknown | — | 65 | Assiut UniversityOTHER | 0 | Mar 29, 2021 | clinicaltrials |
| NCT03800095 | Early Palliative Care for Patients With Haematological Malignancies(CALVI) | unknown | Phase 3 | 140 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01296178 | PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years | unknown | N/A | 200 | PETHEMA FoundationOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT02607059 | Epidemiologic Registry PETHEMA LMA 2015 | unknown | — | 500 | PETHEMA FoundationOTHER | 1 | Mar 23, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 2, 2022source: clinicaltrials